Kepler Capital analyst David Evans maintained a Buy rating on Merck KGaA (0O14 – Research Report) on March 6 and set a price target of ...

In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...

FRANKFURT (Reuters) - Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by ...

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...

Merck KGaA reaffirmed its strong performance in the healthcare sector in its FY 2024 earnings report, but provided little additional information on ongoing acquisition talks with SpringWorks ...

FRANKFURT, March 6 (Reuters) - Merck KGaA (MRCG.DE), opens new tab on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor chemicals and ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KGaA.